News
05-25-2010, 11:41 PM
EpiCept Corporation today announced that the targeted enrollment in a Phase IIb trial for EpiCept NP-1 in chemotherapy-induced peripheral neuropathy has been attained. The trial is being conducted by National Cancer Institute -funded Community Clinical Oncology Program.
More... (http://www.news-medical.net/news/20100526/Targeted-enrollment-in-Phase-IIb-trial-for-EpiCept-NP-1-in-CPN-attained-EpiCept.aspx)
More... (http://www.news-medical.net/news/20100526/Targeted-enrollment-in-Phase-IIb-trial-for-EpiCept-NP-1-in-CPN-attained-EpiCept.aspx)